The Journal of pharmacy and pharmacology · 2025
Berberine-loaded mesoporous silica nanomaterials inhibit pancreatic cancer targeting cancer stem cells.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cao Xihuang, Pang Songyuan, Li Yanping, Song Xue, Tang Huan, Lv Hong, Luo Fuwen, Pan Yue
Аннотация
OBJECTIVES: To investigate the anti-pancreatic ductal adenocarcinoma (PDAC) effect of mesoporous silica nanoparticles loaded with berberine (MSN-BBR) both in vitro and in vivo.
METHODS: Disulfide-bridged MSN loaded with berberine (BBR) was synthesized and characterized. The study assessed the anti-PDAC effect and the impact on the stemness of pancreatic cancer stem cells (PCSCs) in Panc1 cells and mice. Pathological morphology in the pancreas of mice was evaluated through immunohistochemical and immunofluorescence staining, while protein expressions were analyzed via western blot.
KEY FINDINGS: MSN-BBR glutathione-degraded and released BBR. Moreover, MSN-BBR demonstrated the inhibition of Panc1 cell viability and the stemness ability of PCSC by suppressing the epithelial-mesenchymal transition (EMT) pathway. Consistent with these cellular outcomes, MSN-BBR also impeded the growth of pancreatic tumors by specifically targeting PCSC.
CONCLUSIONS: MSN-BBR exhibited degradation and BBR release ability. Notably, MSN-BBR exhibited enhanced efficacy in combating PDAC by selectively focusing on PCSC compared to BBR.
METHODS: Disulfide-bridged MSN loaded with berberine (BBR) was synthesized and characterized. The study assessed the anti-PDAC effect and the impact on the stemness of pancreatic cancer stem cells (PCSCs) in Panc1 cells and mice. Pathological morphology in the pancreas of mice was evaluated through immunohistochemical and immunofluorescence staining, while protein expressions were analyzed via western blot.
KEY FINDINGS: MSN-BBR glutathione-degraded and released BBR. Moreover, MSN-BBR demonstrated the inhibition of Panc1 cell viability and the stemness ability of PCSC by suppressing the epithelial-mesenchymal transition (EMT) pathway. Consistent with these cellular outcomes, MSN-BBR also impeded the growth of pancreatic tumors by specifically targeting PCSC.
CONCLUSIONS: MSN-BBR exhibited degradation and BBR release ability. Notably, MSN-BBR exhibited enhanced efficacy in combating PDAC by selectively focusing on PCSC compared to BBR.